MA-ANIMOL-DISCOVERY
28.7.2022 13:09:06 CEST | Business Wire | Press release
Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, today announced it has raised $34.0 million in Series B financing. The investment was led by Novalis Lifesciences, with participation from Finistere Ventures and existing investor Anterra Capital. The proceeds allow the company to expand and advance its pipeline of novel active pharmaceutical ingredients through clinical development and further enhance its cutting-edge drug discovery platform.
The $40Bn animal health industry continues to demand novel medicines to treat infectious and chronic diseases in companion and production animals. Recent successes, such as Apoquel™ from Zoetis and Nexguard™ from Boehringer Ingelheim, demonstrate the potential to build towards blockbuster franchises in the sector with novel pharmaceutical products.
“Pet parents and livestock farmers continue to demand novel veterinary pharmaceuticals that can protect animals against diseases and improve quality of life,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “Despite this strong demand, innovation is lagging. At Animol, we seek to address this innovation gap by leveraging the most advanced tools from human pharma to bring forward a wealth of new medicines that can benefit animals and the people who care for them.”
Founded in 2020 and incubated by Anterra Capital, Animol is pioneering the use of DNA Encoded Library (DEL) drug discovery technology coupled with powerful machine learning approaches to enable the rapid discovery of novel veterinary medicines.
“We have built Animol on the same cutting edge discovery techniques that we are using to disrupt drug discovery in human pharma (ZebiAI - acquired by Relay Therapeutics) and crop protection (Enko Chem),” said Philip Austin, Managing Partner at Anterra Capital. “Translating these tools to the massive opportunity available in veterinary pharma was the next obvious step and we are already seeing their use successfully build into a rich pipeline of promising compounds.”
Animol also announced that Marijn Dekkers PhD, founder & chairman of Novalis LifeSciences LLC will join the Board of Directors. Dr. Dekkers formerly served as the CEO of Bayer AG, and as the CEO of Thermo Fisher Scientific, Inc. At Bayer he oversaw one of the largest global animal health companies.
“Most current medicines in the $40B veterinary pharma market are derived from drugs that have been originally developed for humans. There is of course nothing wrong with that, but there are many animal-specific diseases that require a targeted effort. I like Animol Discovery’s approach to use its breakthrough drug discovery platform to specifically address significant unmet needs in animals. I am looking forward to working with the team to optimize the opportunity ahead,” said Dr. Dekkers.
“It is a great pleasure to be able to welcome Marijn Dekkers to our Board of Directors. Dr. Dekkers is an exceptional industry leader with a track record of turning innovation into successful businesses across the spectrum of life sciences, including in animal health,” said Andrew Plant PhD, chief executive officer, Animol Discovery. “He is an excellent addition to our team of experienced industry leaders.”
“I am also delighted to bring Doug Hutchens on board as chief scientific officer. Dr. Hutchens brings a wealth of industry experience in animal health research and product development; having someone who has also served as Chief Veterinary Officer within a major animal health company brings huge value to our expanding team,” added Dr. Plant.
“I am thrilled by the prospect of joining Animol’s dynamic and experienced team as chief scientific officer,” said Doug Hutchens, DVM, PhD. “The company’s ability to interrogate protein targets with billions of DNA-tagged molecules and, using DNA sequencing, identify selective inhibitors from numerous diverse chemical families is game changing in animal health drug discovery. Leveraging these data with proprietary, highly predictive machine learning algorithms, is enabling the identification of novel drug-like compounds in a matter of weeks from the initial DEL screen. This technology platform greatly expands the opportunities, significantly increases the probability, and accelerates the timeline in developing new classes of therapeutic molecules.”
About Animol
Animol is a pioneer in using state of the art drug discovery technology to discover small molecule active pharmaceutical ingredients to transform standards of care in veterinary medicine. The company is reducing the time and cost to discover novel active ingredients utilizing DNA-encoded libraries, machine learning/AI and structure-based design.
Animol is a private company based in Boston, Massachusetts. For more information see www.Animol-discovery.com
About Novalis LifeSciences LLC
Novalis LifeSciences LLC is an investment and advisory firm for the Life Science industry that was founded in 2017 by Marijn E. Dekkers. With a team of experienced operating executives from the Life Science industry, Novalis funds and advises visionary Life Science entrepreneurs. In addition to making financial investments, Novalis provides strategic and operational advice to portfolio companies that are at a critical growth stage in their development. For more information, visit www.novalislifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005186/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hytera Debuts SC700 Smart 4G Body Camera at CCW 202630.6.2026 11:30:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/ Hytera's latest SC700 Smart 4G Body Camera Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams. It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or
Global Database Launches Regis, an AI Assistant for Live Company Registry Data30.6.2026 11:13:00 CEST | Press release
Regis gives business users a ChatGPT-like experience for company research, compliance checks, ownership discovery, financial analysis, and prospect list building — powered by live data from official government registries Global Database today announced the launch of Regis, a new AI assistant designed to answer business questions using live company data from official government registries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630229011/en/ Unlike general-purpose AI tools that rely on training data or open web sources, Regis is connected to Global Database’s structured company intelligence platform, covering more than 600 million company profiles, sourced from over 400 government registries across more than 200 countries. For more than a decade, Global Database has been collecting, structuring, and maintaining company data directly from government registries around the world. With the launch of Regis, the company
Kraken Goes Live on Trever to Bring Full-Service Prime Brokerage to European Financial Institutions30.6.2026 10:30:00 CEST | Press release
European banks, brokers and other licensed financial institutions using Trever can now access Kraken Prime’s institutional crypto trading and qualified custody Kraken Prime, the full-service prime brokerage offering trading, qualified custody and other financial services through an integrated platform, is now available through Trever, the operating standard in digital asset banking. Trever’s Digital Asset Operating System is used by financial institutions across Europe to manage the full digital asset lifecycle within a single environment – including trading, treasury, settlement and bookkeeping. From today, banks and brokers using Trever can route execution, settle into qualified custody, record all transactions and access other services through Kraken Prime without leaving their existing operational environment. The integration extends Trever’s connectivity, bringing a prime brokerage relationship into the existing workflows institutional teams use across their digital asset operatio
Microsoft Takes Sisvel Wi-Fi Multimode Patent Pool Licence30.6.2026 10:17:00 CEST | Press release
Microsoft has become a licensee of the Sisvel Wi-Fi Multimode pool. The US computer and software giant is the latest in a string of major companies to take a licence to the standard essential patents offered through the programme. In doing so, it joins ASUS, Hewlett Packard Enterprise and Sony Group Corporation, as well as Huawei, Panasonic, Philips and ZTE which are also pool licensors alongside KPN, Mitsubishi Electric, Orange, Aegis 11 (a Sisvel affiliate), SK Telecom and Wilus. The Sisvel Wi-Fi Multimode pool covers both Wi-Fi 6 and Wi-Fi 7 and offers an efficient way to access essential Wi-Fi rights for years to come. It was publicly launched in January 2026 as the successor to the Sisvel Wi-Fi 6 patent pool. Over a three-year period under that programme, agreements were closed with 40 companies, including Acer, Netgear, Cisco and HP. “It is a pleasure to welcome Microsoft as a licensee of the Sisvel Wi-Fi Multimode pool,” says Alex Debski, Director of Licensing and Counsel Legal
STOKR Secures CASP and PI Licences in Luxembourg Ahead of MiCAR Deadline30.6.2026 10:00:00 CEST | Press release
Authorised by the CSSF just before the 1 July 2026 enforcement deadline, STOKR joins a small group of crypto-asset firms cleared to operate across the EU under a single, harmonised regime. STOKR, the Luxembourg-based digital securities platform, has received authorisation from the Commission de Surveillance du Secteur Financier (CSSF) under the EU's Markets in Crypto-Assets Regulation (MiCAR) and the Law of 10 November 2009 on payment services, securing its Crypto-Asset Service Provider (CASP) and Payment Institution (PI) licences just over a week before MiCAR's 1 July 2026 enforcement deadline. Digital securities fall outside MiCAR's scope but the payment leg does not. To receive, hold, and transfer crypto assets and stablecoins on behalf of clients during subscription and redemption, a platform requires a CASP licence under MiCAR and a PI. Without both, a platform can issue digital securities but cannot move the capital. With MiCAR's transitional period ending on 30 June 2026, a sign
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom